GlassScriptPhysician profile
Keith K Colburn
NPI 1477570869
$12,873.07
in general payments reported to CMS, 2019-2025
28 companies · $2,855 in 2025
The $2,855 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $365 · 2021: $630 · 2022: $1,825 · 2023: $2,410 · 2024: $2,588 · 2025: $2,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,778 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,777.85 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,434.47 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,419.06 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Ucb, INC. | $1,327.86 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,060.31 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $571.54 | 2019-2025 | Tremfya |
| Pfizer INC. | $521.69 | 2019-2025 | |
| Horizon Therapeutics Plc | $519.77 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $463.28 | 2019-2025 | Taltz |
| Astrazeneca Pharmaceuticals LP | $414.94 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $345.32 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $315.12 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $296.00 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.03 | 2022-2024 | Ofev, Cyltezo |
| Octapharma USA, INC. | $123.92 | 2022 | |
| Radius Health, INC. | $122.64 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $119.70 | 2019-2024 | Actemra |
| Ani Pharmaceuticals, INC. | $109.45 | 2024-2025 | Purified Cortrophin Gel |
| Cumberland Pharmaceuticals, INC. | $87.72 | 2022 | |
| Sandoz INC. | $76.83 | 2023-2024 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $58.44 | 2019 | |
| Sobi, INC | $50.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $47.96 | 2021-2023 | Strensiq |
| Genzyme Corporation | $38.73 | 2019 | |
| Fresenius Kabi USA, LLC | $28.13 | 2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $26.73 | 2020 | |
| Organon LLC | $20.88 | 2024 | |
| Bioventus LLC | $19.44 | 2025 | Durolane |
| Tonix Medicines, INC. | $18.79 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Colburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.